Physician profile
Albert B Chang
NPI 1790755569
$16,629.65
in general payments reported to CMS, 2019-2025
60 companies · $2,592 in 2025
The $2,592 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $2,274 · 2021: $2,743 · 2022: $2,787 · 2023: $2,255 · 2024: $2,532 · 2025: $2,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,227 · Travel and Lodging: $135 · Entertainment: $17.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,227.24 |
| Travel and Lodging | $134.50 |
| Entertainment | $17.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,237.66 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,767.61 | 2019-2025 | Ubrelvy, Synthroid, Viberzi |
| Amgen INC. | $1,308.31 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $1,252.69 | 2019-2025 | |
| Novo Nordisk INC | $1,104.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,030.58 | 2019-2025 | Jardiance, Jascayd |
| Nestle Healthcare Nutrition INC. | $857.47 | 2020-2023 | |
| Lilly USA, LLC | $841.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $627.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $564.50 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $453.14 | 2020-2025 | Nexletol, Nexlizet |
| Novartis Pharmaceuticals Corporation | $419.50 | 2021-2025 | |
| Allergan, INC. | $413.63 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $252.09 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $250.86 | 2024-2025 | Zenpep |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $220.57 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.53 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.28 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $174.76 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $168.94 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $157.42 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $156.33 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $156.03 | 2024-2025 | Orgovyx, Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $146.11 | 2022 | |
| Stryker Corporation | $134.50 | 2023 | Everest Spinal System |
| Corcept Therapeutics | $133.40 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $114.77 | 2020-2024 | Zoryve |
| Exact Sciences Corporation | $113.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $97.63 | 2023-2025 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $92.80 | 2025 | Symbravo |
| Radius Health, INC. | $84.19 | 2020-2021 | |
| Abbott Laboratories | $76.91 | 2023-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $69.70 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $67.80 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Eisai INC. | $62.88 | 2020-2021 | |
| Mannkind Corporation | $58.38 | 2019 | |
| Dexcom, INC. | $57.79 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $39.00 | 2021-2022 | |
| Genentech USA, INC. | $35.13 | 2019 | |
| Optos, INC. | $30.46 | 2020-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dermira, INC. | $28.88 | 2020 | |
| Mylan Specialty L.P. | $26.51 | 2022 | |
| Edwards Lifesciences Corporation | $26.30 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vivus LLC | $25.00 | 2022 | |
| Exeltis, USA INC. | $24.88 | 2023 | Slynd |
| Biogen, INC. | $22.85 | 2024 | Leqembi |
| Scilex Pharmaceuticals INC. | $22.84 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2019 | |
| Linus Health, INC. | $20.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.71 | 2023 | Quviviq |
| Astellas Pharma US INC | $18.33 | 2021 | |
| Amryt Pharma Holdings LTD | $18.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.27 | 2021 | |
| Daiichi Sankyo INC. | $18.09 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.71 | 2019 | |
| Lucid Diagnostics INC. | $16.49 | 2022 | |
| Cequr Corporation | $16.08 | 2024 | Cequr Simplicity |
| Vbi Vaccine (Delaware) INC. | $15.56 | 2022 | |
| Medtronic, INC. | $13.99 | 2022 | |
| Intra-Sana Laboratories | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.